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Abstract
Background: While survival rates of extremely preterm infants have improved over the last decades, the incidence
of neurodevelopmental disability (ND) in survivors remains high. Representative current data on the severity of
disability and of risk factors associated with poor outcome in this growing population are necessary for clinical
guidance and parent counselling.
Methods: Prospective longitudinal multicentre cohort study of preterm infants born in Switzerland between 240/7
and 276/7 weeks gestational age during 2000–2008. Mortality, adverse outcome (death or severe ND) at two years,
and predictors for poor outcome were analysed using multilevel multivariate logistic regression. Neurodevelopment
was assessed using Bayley Scales of Infant Development II. Cerebral palsy was graded after the Gross Motor
Function Classification System.
Results: Of 1266 live born infants, 422 (33%) died. Follow-up information was available for 684 (81%) survivors: 440
(64%) showed favourable outcome, 166 (24%) moderate ND, and 78 (11%) severe ND. At birth, lower gestational
age, intrauterine growth restriction and absence of antenatal corticosteroids were associated with mortality and
adverse outcome (p < 0.001). At 360/7 weeks postmenstrual age, bronchopulmonary dysplasia, major brain injury
and retinopathy of prematurity were the main predictors for adverse outcome (p < 0.05). Survival without moderate
or severe ND increased from 27% to 39% during the observation period (p = 0.02).
Conclusions: In this recent Swiss national cohort study of extremely preterm infants, neonatal mortality was determined
by gestational age, birth weight, and antenatal corticosteroids while neurodevelopmental outcome was determined by
the major neonatal morbidities. We observed an increase of survival without moderate or severe disability.
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Background
Advances in perinatal care have resulted in improved sur-
vival rates of extremely preterm infants over the last three
decades [1]. In contrast, the incidence of major neonatal
diseases causing significant morbidity in this population
remains unchanged [2]. Long-term outcome studies indi-
cate higher vulnerability in a wide spectrum of develop-
mental domains, ranging from somatic growth, learning
abilities, behaviour, and motor performance to sensorial
domains [3-8]. As a consequence, the high proportion of
infants surviving with long-term neurosensory disabilities
is cause of major concern. Gestational age, birth weight,
sex, multiple birth, antenatal corticosteroid administration,
neonatal infection, necrotizing enterocolitis (NEC),
bronchopulmonary dysplasia (BPD), and major brain
lesions such as periventricular leukomalacia (PVL) and
intraventricular haemorrhage (IVH) have been shown to
influence both short- and long-term outcome [9-11]. The
analysis of outcomes in this population represents a cru-
cial aspect of quality control and may identify risk factors
that could potentially be targeted by specific intervention
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measures. In addition, decisions on the provision of inten-
sive versus palliative care and counselling of parents of ex-
tremely preterm infants are based on the expected
incidence of mortality and poor long-term outcome.
Therefore, it is of paramount importance that representa-
tive and recent outcome data are available [10,12-14]. The
present study aimed to describe the outcomes of a recent
Swiss cohort of extremely premature infants at two years
of age and to establish the main risk factors to predict
mortality, and adverse and favourable outcome.
Methods
Study population
This was a prospective longitudinal multicentre cohort
study including extremely premature infants live born
between 240/7 and 276/7 weeks in Switzerland from Janu-
ary 1st 2000 to December 31st 2008. Routine follow-up
of infants below 280/7 weeks gestational age has been
recommended and performed by the Swiss Neonatal
Follow-up Group since 2000, and follow-up data are
prospectively collected in the network database. After
the recommendation was issued to base follow-up exam-
inations on the Bayley Scales of Infant Development II
(BSID-II) [15], not all centres were able to implement
this immediately. Therefore, only infants from centres
routinely assessing BSID-II were included for the analysis.
Infants with major congenital malformations (defined as
genetic anomaly, syndrome, or malformation of a major
organ system) were excluded. Clinical and follow-up data
for this study were prospectively recorded in the national
database of the Swiss Neonatal Network & Follow-up
Group. Data collection and evaluation for this study were
approved by the institutional ethical review boards and by
the Swiss Federal Commission for Privacy Protection in
Medical Research. Participating centres were obliged to in-
form parents about the scientific use of anonymized data.
Definition of neonatal variables
Gestational age was the best estimate available from the
obstetric measurements based on last menstrual period or
prenatal ultrasound findings, as recorded in the maternal
chart. Birth weight z-scores were calculated based on the
growth curves by Voigt et al. [16]. Major brain injury was
defined as IVH grade 3 or higher according to Papile clas-
sifications [17] and/or presence of cystic PVL [18] on
cerebral ultrasound. Bronchopulmonary dysplasia (BPD)
was defined as requirement for additional oxygen at 360/7
weeks postmenstrual age (PMA) [19]. Retinopathy of pre-
maturity (ROP) was defined using the International Com-
mittee criteria [20]. NEC was defined as pneumatosis
intestinalis or pneumatosis vena portae (Bell’s stage two or
higher) [21]. The presence or absence of infection was
classified into uninfected, suspected (clinical and labora-
tory signs of sepsis but absence of positive blood or
cerebrospinal fluid culture, in an infant who received
treatment with antibiotics for ≥ 5 days or until death), and
proven sepsis (positive blood or cerebrospinal fluid cul-
ture) [22]. Socioeconomic status (SES) was estimated by a
validated 12-point socioeconomic score based on mater-
nal education and paternal occupation and was classified
into higher class (score 2–5), middle class (6–8) and lower
class (9–12) [23].
Neurodevelopmental assessment
Neurodevelopmental examination was routinely performed
by experienced developmental paediatricians or neuropae-
diatricians at each Swiss Neonatal Follow-up centre at
18–24 months corrected age (i.e. the age the infant would
be if he had been born on his due date). The assessment
consisted of a clinical examination, a structured neuro-
logical assessment and a developmental assessment using
the BSID-II [15]. Vision and hearing were assessed either
by direct examination or caregiver report. If a structured
BSID-II testing could not be performed due to lack of co-
operation, the exam was repeated 3 to 6 months later.
Infants who were so severely impaired that a structured
testing with the BSID-II could not be performed were
assigned a mental development index (MDI) and psycho-
motor development index (PDI) of 49. Cerebral palsy (CP)
was defined as a permanent disorder of movement and
posture, causing activity limitations that are attributed to
non-progressive disturbances that occurred in the develop-
ing fetal or infant brain [24] and was graded according to
the Gross Motor Function Classification System of Palisano
and associates for children aged ≤ 2 years [25].
Outcome definitions
Outcome at two years of age was defined according to
the guidelines of the working group of the British Asso-
ciation of Perinatal Medicine and the National Neonatal
Audit Project on the Classification of Health Status [26]:
i) Death before two years of age.
ii) Severe neurodevelopmental disability; defined as CP
with GMFCS level 3–5; or a BSID-II score of < −3SD
below the mean (i.e. MDI or PDI <55), or absence of
useful hearing even with aids (i.e. >90dB hearing
level), or blindness or only perception of light or light
reflecting objects.
iii)Moderate neurodevelopmental disability; defined as
CP with GMFCS level 2, or a BSID-II score between −3
and −2 SD below the mean (i.e. MDI or PDI 55–69), or
hearing loss corrected with aids (40-90dB hearing level),
or moderately reduced vision but better than severe
visual disability, or unilateral blindness with good vision
in the contralateral eye.
iv) Favourable outcome; defined as absence of any of
the above.
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Adverse outcome was defined as the combination of
death or severe ND. Unfavourable outcome was defined
as the combination of death, or severe or moderate ND.
Statistical analysis
Chi-square test and Mann–Whitney U test were used to
compare subgroups in nonadjusted comparisons.
Two different time points were chosen for the outcome
prediction models:
i) at time of birth: this dataset included all live born
children, and the covariates known at birth
ii) at 360/7 weeks PMA: this dataset included all infants
surviving up to 360/7 weeks PMA, and the covariates
known by 360/7 weeks PMA.
We first selected the clinical and demographic vari-
ables known to determine mortality and adverse out-
come based on evidence from the literature [8,27]. We
then checked these associations in our population using
univariate logistic regression analysis. This was per-
formed both in all infants being born and in all infants
surviving to 360/7 weeks PMA. Pre-planned sensitivity
analyses were performed excluding children who died in
the delivery room since many of these children were a
priori treated in a palliative way. We used random-
effects multi-level regression models with centre-specific
intercepts to allow for clustering on the study centre
level (9 centres) and for year of birth (2000 – 2002; 2003
– 2005; 2006–2008). We then performed multivariate
regression analysis for each of the outcome parameters.
For multivariate analyses, all explanatory variables that
showed an association (p-value <0.10) in the univariate
analysis with consistent findings in sensitivity analyses or
that are known to act as a confounder were included.
The following covariates are included in analyses asses-
sing outcome prediction at birth: gestational age (weeks
plus days), birth weight z-score (since birth weight was
highly collinear with gestational age), sex, antenatal cor-
ticosteroids and multiple birth. The following covariates
are included in analyses assessing outcome prediction at
36 weeks PMA: gestational age (weeks plus days), birth
weight z-score, sex, antenatal corticosteroids, multiple
birth, PDA, NEC, sepsis, ROP stage 3 or higher, BPD,
major brain injury and socioeconomic class.
A logistic regression model was calculated to predict ad-
verse and unfavourable outcome after 360/7 weeks PMA.
BPD, major brain injury, ROP stage 3 or higher, and NEC
or proven sepsis were selected for the model given their
strong association with outcomes. The risk for adverse
and for favourable outcome was estimated according to
whether one, two, three or four of the risk factors were
diagnosed in an infant. Associations are given as Odd’s
ratios (OR) with 95%-confidence intervals (95% CI) and
the two-sided p-values. All analyses were performed using
STATA 12.2 (STATA Corporation, College Station, TX,
USA) and R for the models with splines.
Results
Study population
During the study period, 1326 infants were born alive
with a gestational age of 240/7 and 276/7 weeks. Of those,
60 were excluded due to major congenital malforma-
tions. Of the included 1266 extremely preterm infants,
422 (33%) infants died: 130 died in delivery room, 280
died after delivery room but before 360/7 weeks PMA,
and 12 died between 360/7 weeks PMA and two years of
corrected age. Of the 844 surviving infants, 160 (19%)
did not receive BSID-II testing and were excluded from
the analysis: 109 (13%) infants were lost to follow-up (40
refused follow-up, 53 could not be reached/moved away,
16 unknown loss to follow-up), and 51 (6%) were evalu-
ated using other tests. Children not tested with the
BSID-II had a significantly higher gestational age and
birth weight, and were more likely to be outborn, deliv-
ered by vaginal delivery, and less likely to have BPD than
those tested with the BSID-II (Table 1). BSID-II evalu-
ation was thus performed in 684/844 (81%) surviving
infants at a median corrected age of 23 months (inter-
quartile range 21 to 25 months). Of the children tested
with BSID-II, 440/684 (64%) showed favourable out-
come, 166 (24%) moderate ND and 78 (11%) severe ND.
Mortality and adverse outcome decreased significantly
over the three 3-year observation periods (for mortality:
44%, 32%, 28%; p = 0.01; for adverse outcome 52%, 39%,
33%; p = 0.001; Figure 1). Survival without moderate or se-
vere neurodevelopmental disability increased significantly
over the observation periods (27%, 36%, 39%; p = 0.016).
Outcome prediction at time of birth
An overview of the outcomes in relation to the main risk
factors is shown in Table 2. Univariate analyses showed
that lower gestational age and lower birth weight z-score
were significantly associated with mortality, with adverse
outcome, and with unfavourable outcome (Table 3). The
relationship between gestational age and outcome was
linear, whereas the relationship between birth weight
and outcome was non-linear with the highest OR in
children with a z-score of < −2 (Figure 2). Completion of
antenatal corticosteroids for fetal lung maturation induc-
tion showed a protective effect on all three outcomes.
Multivariate analyses confirmed the strong association
of lower gestational age, lower birth weight z-score, and
absence of antenatal corticosteroids with all outcomes
(Table 3). Male sex was significantly associated with ad-
verse and unfavourable outcome, while in- versus out-
born delivery and singleton versus multiple pregnancy
were not associated with outcome. In sensitivity analyses
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excluding infants that died in the delivery room (Table 4),
caesarean delivery was not associated with a reduced risk
for any of the outcomes.
Outcome prediction at 360/7 weeks PMA
When restricting the dataset to infants surviving to 360/7
weeks PMA, univariate analyses showed that adverse
outcome was associated with male sex, NEC, sepsis, dur-
ation of mechanical ventilation, BPD, major brain in-
jury, cystic PVL, and ROP. Unfavourable outcome
was associated with lower gestational age, severe
growth restriction, sepsis, duration of mechanical ven-
tilation, BPD, cystic PVL, ROP and lower SES class
(Table 5).
In multivariate models, adverse outcome was signifi-
cantly associated with BPD, major brain injury and ROP
(Table 5). The presence of BPD was the single strongest
predictor for adverse outcome (OR 2.81; 95%-CI 1.59 –
4.96; p < 0.001). Unfavourable outcome was significantly
associated with BPD, ROP and lower socioeconomic
class, whereas major brain injury and severe growth re-
striction were trend wise associated (Table 5). The pres-
ence of ROP stage 3 or higher was the single strongest
predictor for unfavourable outcome (OR 4.88; 95%-CI
2.07 – 11.52; p < 0.001).
Prediction model of outcome using count of major
neonatal morbidities
The risk for adverse and for unfavourable outcome
increased strongly with each addition of a major neo-
natal risk factor (BPD, major brain injury, ROP stage 3
or higher, NEC or proven sepsis), with a p-value of
<0.001). Infants with none of the risk factors had an ad-
verse outcome in 6% and had a favourable outcome in
71% (Figure 3). Infants with three risk factors had an ad-
verse outcome in 40% and a favourable outcome
in 20%.
Figure 1 Changes in mortality and in frequency of severe and moderate neurodevelopmental disability during the study period.
FU, follow-up; ND, neurodevelopmental disability.
Table 1 Comparison of baseline and neonatal
characteristics of infants who had received a BSID-II
testing versus infants who survived to follow-up but who
did not receive a BSID-II testing
BSID-II
(n = 684)
No BSID-II
(n = 160)
N (%) N (%) p-value§
Median (IQR) Median (IQR)
Inborn 654 (96%) 144 (90%) 0.005
Male gender 362 (53%) 89 (56%) 0.54
Gestational age [weeks] 26.7 (25.9-27.3) 27 (26.1-27.6) 0.007
Birth weight [gram] 855 (730–990) 940 (800–1100) <0.001
SGA 52 (8%) 7 (5%) 0.15
Singleton 487 (71%) 121 (76%) 0.26
Antenatal corticosteroids
(completed)
441 (69%) 99 (65%) 0.29
Caesarean delivery 552 (81%) 117 (73%) 0.028
SES score 6 (4–8) 6 (4–8) 0.72
Umbilical artery pH 7.31 (7.25-7.35) 7.30 (7.23-7.34) 0.17
PDA 311 (46%) 62 (39%) 0.12
PDA ligation 55 (8%) 15 (9%) 0.58
Mechanical ventilation 505 (79%) 109 (73%) 0.14
Mechanical ventilation [days] 4 (1–10) 4 (0–8) 0.20
Bronchopulmonary dysplasia 139 (21%) 18 (11%) 0.008
IVH > 2 46 (7%) 8 (5%) 0.42
Major brain injury 61 (9%) 10 (6%) 0.27
ROP stage 3 or higher 35 (5%) 8 (6%) 0.77
Proven sepsis 171 (25%) 32 (20%) 0.18
Necrotizing enterocolitis 18 (3%) 2 (1%) 0.30
§ p-value of Chi-square test (for ratios) and p-value of Mann–Whitney U test (for
linear variables); IQR, interquartile range; IVH, intraventricular haemorrhage; NEC,
necrotizing enterocolitis; PDA, persistent ductus arteriosus; ROP, retinopathy
of prematurity; SES, socioeconomic score; SGA, small for gestational age
(<10th percentile).
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Table 2 Overview of outcomes in the entire cohort in relation to gestational age, birth weight, gender, and antenatal
corticosteroids
Gestational age
240/7 to 246/7 250/7 to 256/7 260/7 to 266/7 270/7 to 276/7 Total
N % N % N % N % N %
Favourable outcome 28 13 76 28 140 40 196 45 440 35
Moderate ND 18 9 36 13 51 15 61 14 166 13
Severe ND 11 5 18 7 21 6 28 6 78 6
Died after delivery room 61 29 90 33 76 22 65 15 292 23
Died in delivery room 87 41 28 10 8 2 7 2 130 10
Survived, no FU 5 2 23 8 50 14 82 19 160 13
Total 210 100 271 100 346 100 439 100 1266 100
Birth weight
< 500g 500-749g 750-999g > 999g Total
N % N % N % N % N %
Favourable outcome 4 9 110 27 211 40 115 42 440 35
Moderate ND 5 11 44 11 82 15 35 13 166 13
Severe ND 1 2 25 6 36 7 16 6 78 6
Died after delivery room 22 49 119 29 112 21 39 14 292 23
Died in delivery room 12 27 83 20 25 5 3 1 123 10
Survived, no FU 1 2 29 7 65 12 65 24 160 13
Total 45 100 410 100 531 100 273 100 1259 100
Sex
female male Total
N % N % N %
Favourable outcome 218 37 222 33 440 35
Moderate ND 75 13 91 13 166 13
Severe ND 29 5 49 7 78 6
Died after delivery room 128 22 164 24 292 23
Died in delivery room 64 11 65 10 129 10
Survived, no FU 71 12 89 13 160 13
Total 585 100 680 100 1265 100
Antenatal corticosteroids
incomplete/none completed Total
N % N % N %
Favourable outcome 140 28 296 41 436 35
Moderate ND 53 10 113 16 166 13
Severe ND 24 5 53 7 77 6
Died after delivery room 139 27 150 21 289 23
Died in delivery room 95 19 16 2 111 9
Survived, no FU 58 11 99 14 157 13
Total 509 100 727 100 1236 10
Died, patient died in NICU or after discharge from the NICU; died in delivery room, patient died in the delivery room; FU, follow-up; ND, neurodevelopmental
disability.
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Discussion
This study reports on mortality and outcome at two
years of age in extremely preterm infants in a Swiss co-
hort born after 2000, based on a nationwide prospective
registry and follow-up program. Thereby it provides rep-
resentative outcome information on a national level over
a nine-year period. To the best of our knowledge, these
data represent one of the largest datasets on a recent
birth cohort.
The incidence of severe ND was 11%, while 24% of
infants survived with moderate ND. The overall rate of
any ND was moderately higher than reported in a simi-
lar cohort born in 2005 in Victoria, Australia [28]. Mor-
tality depended strongly on gestational age and
decreased from 70% at 24 weeks to 17% at 27 weeks.
The observed mortality rates were slightly higher com-
pared to a U.S. cohort [29] and a recent Australian co-
hort [28], but similar to European data [30]. We
Table 3 Outcome prediction at birth: uni- and multivariate association of clinical and demographic parameters known
at birth with mortality, adverse outcome and unfavourable outcome
MORTALITY Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.39 (0.34 - 0.44) <0.001 0.40 (0.35 - 0.47) <0.001
BW z-score 0.64 (0.56 - 0.74) <0.001 NA
BW z-score < −2 6.99 (3.09 - 15.85) <0.001 11.68 (4.73 - 28.86) <0.001
BW z-score −2 to −1 2.10 (1.46 - 3.03) <0.001 2.71 (11.78 - 4.12) <0.001
Male sex 1.06 (0.82 - 1.35) 0.67 1.15 (0.86 - 1.54) 0.33
Outborn 0.80 (0.45 - 1.45) 0.47 NA
Antenatal corticosteroids 0.34 (0.26 - 0.44) <0.001 0.46 (0.34 - 0.62) <0.001
Caesarean delivery 0.49 (0.37 - 0.65) <0.001 NA
Multiple pregnancy 1.02 (0.77 - 1.34) 0.90 1.27 (0.91 - 1.78) 0.16
ADVERSE OUTCOME Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.47 (0.41 - 0.53) <0.001 0.49 (0.42 - 0.56) <0.001
BW z-score 0.71 (0.62 - 0.88) <0.001 NA
BW z-score < −2 5.36 (2.22 - 12.90) <0.001 7.90 (3.08 - 20.25) <0.001
BW z-score −2 to −1 1.91 (1.32 - 2.78) <0.001 2.35 (1.59 - 3.55) <0.001
Male sex 1.20 (0.94 - 1.54) 0.15 1.34 (1.01 - 1.77) 0.042
Outborn 0.98 (0.53 - 1.81) 0.95 NA
Antenatal corticosteroids 0.40 (0.31 - 0.53) <0.001 0.51 (0.38 - 0.69) <0.001
Caesarean delivery 0.53 (0.39 - 0.70) <0.001 NA
Multiple pregnancy 0.96 (0.73 - 1.27) 0.80 1.19 (0.87 - 1.64) 0.28
UNFAVOURABLE OUTCOME Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.52 (0.45 - 0.59) <0.001 0.54 (0.47 - 0.61) <0.001
BW z-score 0.73 (0.63 - 0.85) <0.001 NA
BW z-score < −2 12.05 (2.82 - 51.48) <0.001 16.91 (3.84 - 74.47) <0.001
BW z-score −2 to −1 1.59 (1.08 - 2.33) 0.019 1.82 (1.20 - 2.74) 0.004
Male sex 1.24 (0.96 - 1.59) 0.09 1.35 (1.02 - 1.77) 0.033
Outborn 1.30 (0.68 - 2.49) 0.42 NA
Antenatal corticosteroids 0.48 (0.36 - 0.63) <0.001 0.57 (0.43 - 0.77) <0.001
Caesarean delivery 0.69 (0.51 - 0.93) <0.001 NA
Multiple pregnancy 1.05 (0.79 - 1.38) 0.76 1.31 (0.96 - 1.78) 0.087
The table gives all parameters that showed an unequal distribution among groups as shown in Table I or that are known from previous publications to act as
confounders. † The univariate model is adjusted for study centre and year group. ‡ The multivariate model contains all parameters that were associated with the
outcome in the univariate model.
CI, confidence interval; OR, Odd’s ratio; BW, birth weight.
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observed a significant decrease in mortality and severe
ND over the study period with a parallel increase in sur-
vival without moderate or severe neurodevelopmental
disability. This trend is supported by the observed over-
all decrease in major neonatal morbidities in preterm
infants during the last decade in Switzerland [31]. How-
ever, some caution is required when interpreting the
observed trend since implementation of BSID-II
increased between 2000 and 2005 in the participating
centres. We therefore adjusted analyses using random
multilevel clustering for each centre in order to account
for the effect of centre-to-centre differences. Since this is
a purely observational cohort on neonatal morbidities
and outcomes, it is not possible at this stage to identify
specific changes in management that potentially could
have led to improved outcomes over time. Theoretically,
a variety of factors such as improved prenatal care, early
start of CPAP, optimal feeding and strategies to reduce
nosocomial infection may contribute to improved out-
comes. The publication of the Swiss guidelines [32] for
the care of infants between 22 and 26 gestational weeks
in 2002 may have affected the decision to provide pallia-
tive versus intensive care in infants below 26 weeks GA.
Therefore, this study was based only on infants born
after at least 24 0/7 weeks PMA and we performed sen-
sitivity analyses excluding infants that died in delivery
room. The sensitivity analyses confirmed the main
results.
At birth, death and severe ND were mainly predicted
by low gestational age and low birth weight, while ante-
natal corticosteroids to induce fetal lung maturation had
a strong protective effect. Male sex increased the risk of
adverse outcome, but it played a minor role compared
to previous reports [12,13]. Surprisingly, outborn and
multiple birth status did not affect outcome prediction
in our cohort, but the rate of outborns was small. In the
past, the majority of publications reporting on neonatal
outcomes used both gestational age and birth weight as
covariates, despite the strong collinearity between these.
We think our model is more accurate, since birth weight
Figure 2 Spline figures showing non-linear associations of gestational age and birth weight with mortality (A, B) and with adverse
outcome (C, D). The birth weight z-score (A, C) and the gestational age in weeks (B, D) are given on the X-axis. Each mark on the X-axis
represents a patient. In panel B and D the duration of gestational age was rounded to one decimal. The natural logarithm of the multivariate
Odd’s ratio for the respective outcome is shown (y-axis and solid line) with the 95%-confidence intervals (dashed lines).
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is not an independent variable, but a result of gestational
age and intrauterine growth (z-score of birth weight).
Multivariate analyses confirmed that the z-score of birth
weight was strongly associated with outcomes. Whether
caesarean delivery has a protective effect is debated in
the literature [33,34]. In our study, delivery by caesarean
delivery showed a protective benefit in the univariate
risk analysis, but this effect disappeared in the sensiti-
vity analyses, suggesting the association was strongly
confounded by the antenatal decision to treat a child in
a palliative way and thus avoiding caesarean delivery.
Additional multivariate analyses including delivery mode
as a covariate resulted highly similar to the main models
and caesarean delivery was not significantly associated
with any of the outcomes (data not shown).
Long-term outcome in children surviving to 360/7
weeks PMA was only weakly influenced by the main
perinatal factors gestational age, intrauterine growth, sex
Table 4 Outcome prediction at birth: sensitivity analyses excluding infants that died in delivery room (n = 130):
Uni- and multivariate association of clinical and demographic parameters known at birth with mortality, adverse
outcome and unfavourable outcome
MORTALITY Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.47 (0.41 - 0.55) <0.001 0.46 (0.39 - 0.54) <0.001
BW z-score 0.66 (0.56 - 0.77) <0.001 NA
BW z-score < −2 6.92 (2.89 - 16.59) <0.001 10.09 (4.01 - 25.40) <0.001
BW z-score −2 to −1 2.02 (1.35 - 3.02) <0.001 2.52 (1.63 - 3.90) <0.001
Male sex 1.13 (0.86 - 1.49) 0.38 1.16 (0.86 - 1.57) 0.33
Outborn 1.15 (0.64 - 2.06) 0.65 NA
Antenatal corticosteroids 0.52 (0.39 - 0.70) <0.001 0.55 (0.41 - 0.76) <0.001
Caesarean delivery 0.77 (0.55 - 1.06) 0.1 NA
Multiple pregnancy 0.94 (0.69 - 1.29) 0.72 1.28 (0.90 - 1.81) 1.17
ADVERSE OUTCOME Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.56 (0.49 - 0.65) <0.001 0.55 (0.47 - 0.64) <0.001
BW z-score 0.73 (0.62 - 0.85) <0.001 NA
BW z-score < −2 4.99 (1.98 - 12.56) <0.001 6.74 (2.58 - 17.60) <0.001
BW z-score −2 to −1 1.82 (1.22 - 2.72) 0.003 2.20 (1.44 - 3.36) <0.001
Male sex 1.29 (0.98 - 1.69) 0.066 1.35 (1.01 - 1.80) 0.041
Outborn 1.34 (0.73 - 2.47) 0.34 NA
Antenatal corticosteroids 0.58 (0.44 - 0.78) <0.001 0.61 (0.45 - 0.83) 0.002
Caesarean delivery 0.79 (0.57 - 1.09) 0.15 NA
Multiple pregnancy 0.91 (0.67 - 1.23) 0.55 1.17 (0.85 - 1.63) 0.34
UNFAVOURABLE OUTCOME Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.60 (0.52 - 0.68) <0.001 0.59 (0.51 - 0.68) <0.001
BW z-score 0.75 (0.64 - 0.87) <0.001 NA
BW z-score < −2 11.32 (2.60 - 49.16) 0.001 15.24 (3.43 - 67.71) <0.001
BW z-score −2 to −1 1.47 (0.96 - 2.19) 0.059 1.69 (1.12 - 2.57) 0.013
Male sex 1.30 (1.00 - 1.67) 0.049 1.35 (1.02 - 1.78) 0.033
Outborn 1.65 (0.87 - 3.15) 0.13 NA
Antenatal corticosteroids 0.64 (0.48 - 0.86) 0.002 0.66 (0.49 - 0.89) 0.006
Caesarean delivery 0.96 (0.70 - 1.33) 0.82 NA
Multiple pregnancy 1.01 (0.76 - 1.35) 0.94 1.29 (0.94 - 1.76) 0.11
The table gives all parameters that showed an unequal distribution among groups as shown in Table I or that are known from previous publications to act as
confounders. † The univariate model is adjusted for study centre and year group. ‡ The multivariate model contains all parameters that were associated with the
outcome in the univariate model.
OR, Odd’s ratio; CI, confidence interval; BW, birth weight.
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Table 5 Outcome prediction at 36 weeks gestational age: uni- and multivariate association of clinical and demographic
parameters present by 36 weeks gestational age with adverse outcome, and with unfavourable outcome
ADVERSE OUTCOME (severe ND or death after 360/7 weeks PMA versus favourable outcome or moderate ND)
Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.81 (0.65 - 1.02) 0.077 1.00 (0.76 - 1.32) 0.98
BW z-score 0.85 (0.64 - 1.13) 0.271 NA
BW z-score < −2 1.19 (0.14 - 10.2) 0.88 0.70 (0.08 - 6.33) 0.75
BW z-score −2 to −1 1.33 (0.68 - 2.62) 0.41 1.22 (0.56 - 2.67) 0.62
Male sex 1.60 (1.00 - 2.54) 0.049 1.35 (0.79 - 2.24) 0.27
Antenatal corticosteroids 1.17 (0.70 - 1.96) 0.55 0.86 (0.49 - 1.51) 0.61
Multiple pregnancy 0.96 (0.58 - 1.60) 0.88 1.34 (0.77 - 2.36) 0.3
PDA 1.52 (0.95 - 2.43) 0.083 1.29 (0.77 - 2.17) 0.33
NEC 5.45 (2.25 - 13.22) <0.001 1.94 (0.58 - 6.50) 0.28
Sepsis 1.47 (1.10 - 1.95) 0.008 1.20 (0.87 - 1.65) 0.27
Duration of ventilation (days) 1.04 (1.02 - 1.06) <0.001 NA
Mechanical ventilation 3.50 (1.55 - 7.93) 0.003 NA
BPD 3.09 (1.89 - 5.03) <0.001 2.81 (1.59 - 4.96) <0.001
IVH ≥3 1.84 (0.86 - 3.93) 0.11 NA
Cystic PVL 2.07 (1.40 - 3.05) <0.001 NA
Major brain injury 2.72 (1.45 - 5.10) 0.002 2.64 (1.28 - 5.43) 0.008
ROP ≥3 2.73 (1.21 - 6.14) 0.015 2.56 (1.05 - 6.26) 0.039
SES class 0.74 (0.53 - 1.03) 0.078 0.74 (0.51 - 1.06) 0.096
UNFAVOURABLE OUTCOME (moderate or severe ND or death after 360/7 weeks PMA versus favourable outcome)
Univariate model† Multivariate model‡
OR (95%-CI) p-value OR (95%-CI) p-value
Gestational age (weeks) 0.76 (0.65 - 0.90) 0.001 0.90 (0.74 - 1.10) 0.31
BW z-score 0.85 (0.70 - 1.04) 0.11 NA
BW z-score < −2 6.52 (1.26 - 33.79) 0.025 5.29 (0.91 - 30.84) 0.064
BW z-score −2 to −1 1.04 (0.63 - 1.73) 0.88 0.95 (0.54 - 1.68) 0.86
Male sex 1.35 (0.98 - 1.86) 0.063 1.16 (0.81 - 1.65) 0.42
Antenatal corticosteroids 0.97 (0.68 - 1.38) 0.85 0.73 (0.49 - 1.09) 0.12
Multiple pregnancy 1.11 (0.78 - 1.58) 0.58 1.31 (0.88 - 1.96) 0.18
PDA 1.17 (0.84 - 1.63) 0.35 1.05 (0.73 - 1.53) 0.78
NEC 2.34 (0.99 - 5.52) 0.052 1.22 (0.43 - 3.49) 0.71
Sepsis 1.26 (1.03 - 1.54) 0.026 1.10 (0.87 - 1.38) 0.42
Duration of ventilation (days) 1.03 (1.02 - 1.05) <0.001 NA
Mechanical ventilation 1.23 (0.81 - 1.87) 0.32 NA
BPD 2.26 (1.53 - 3.33) <0.001 1.92 (1.24 - 2.99) 0.004
IVH ≥3 1.35 (0.74 - 2.48) 0.33 NA
Cystic PVL 1.43 (1.04 - 1.98) 0.03 NA
Major brain injury 1.68 (0.99 - 2.86) 0.054 1.74 (0.95 - 3.18) 0.07
ROP ≥3 5.03 (2.33 - 10.86) <0.001 4.88 (2.07 - 11.52) <0.001
SES class 0.76 (0.61 - 0.96) 0.022 0.74 (0.58 - 0.95) 0.018
The table gives all parameters that showed an unequal distribution among groups as shown in Table I or that are known from previous publications to act as
confounders. † The univariate model is adjusted for study centre. ‡ The multivariate model contains all parameters that were associated with the outcome in the
univariate model plus demographic factors such as gender and birth weight.
ND, neurodevelopmental disability; OR, Odd’s ratio; CI, confidence interval; PMA, postmenstrual age; BW, birth weight; PDA, persistent ductus arteriosus; NEC,
necrotizing enterocolitis ≥ stage 2; BPD, bronchopulmonary dysplasia; major brain injury, intraventricular haemorrhage ≥ grade 3 or cystic periventricular
leukomalacia; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity ≥ stage 3; SES, socioeconomic status.
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and lung maturation. Instead, the major neonatal mor-
bidities such as BPD, ROP, major brain injury and NEC
or sepsis played a major role. Our results are in agree-
ment with a previous study reporting that the prognosis
for very preterm infants changes during the course of
early postnatal life depending on the incidence of neo-
natal morbidities [35]. Our findings confirm that ante-
natal corticosteroids improve survival without increasing
morbidity in the survivors [36]. NEC and sepsis were
strongly associated with outcomes in univariate analyses,
which is in agreement with previous studies [10,22].
However, in multivariate models, BPD was the single
strongest predictor of adverse outcome, while ROP, fol-
lowed by BPD, was the strongest predictor of
unfavourable outcome. Interestingly, further analyses
revealed that sepsis was one of the strongest risk factors
for BPD (multivariate p = 0.006), together with low gesta-
tional age, intrauterine growth restriction and absence of
antenatal corticosteroids. This indicates that while BPD in
our model is the better predictor of adverse outcome, sep-
sis represents one of the main causative factors leading to
BPD. It is important but often difficult to distinguish
whether a covariate is a marker of disease severity or actu-
ally a factor causing poor outcome. Mechanical ventilation
and sepsis are known to cause direct damage to the lungs
and, indirectly, to the brain [37].
Several limitations of this study need to be mentioned.
Nineteen percent of surviving infants did not receive
BSID-II testing and were excluded from the logistic re-
gression analyses. Even if our follow-up rate of 81% is
comparable to published studies [38], the infants lost from
follow-up displayed a higher GA and a lower BPD rate
than the study group. We cannot exclude that the loss
from follow-up of these infants may have led to a slight
underestimation of the overall outcome. We decided a
priori to predict outcome at two time points, once at time
of birth and once at 36 weeks gestational age. The selec-
tion of these two time points makes sense from a clinical
point of view, since outcome prediction is most important
pre-delivery and when approaching discharge. However,
this model does not allow assessing the impact of the main
postnatal morbidities on early neonatal mortality. Since
data on chorioamnionitis and postnatal corticosteroids
therapy were not prospectively recorded, we cannot com-
ment on the impact of these two factors [39,40] on out-
come. Finally, outcome assessment at two years of age
may both over - and underestimate long-term cognitive
and motor neurodevelopment [41].
The strengths of this study include the fact that it is
based on a large national prospective database. The def-
inition of neurodevelopmental outcomes was based on a
recent consensus definition. The definition of severe ND
required extremely low cognitive or motor perfor-
mances, i.e. <−3SD, and/or severe neurosensory disabil-
ities, thus identifying severely disabled children. In
comparison, the definition of neurodevelopmental dis-
ability used in several previous studies overlaps with our
definition of severe and moderate ND [11,22,42]. The
uni- and multivariate statistical models were highly simi-
lar, confirming the independent contribution of the
major risk factors on outcome.
Conclusions
This population-based study of extremely preterm
infants shows that, although more than a third of infants
still suffer from moderate or severe ND, the rate of sur-
vival without major neurologic sequelae has increased
significantly over the last decade, while the mortality rate
Figure 3 Model of prediction of outcome according to count of
four risk factors (bronchopulmonary dysplasia, major brain
injury, retinopathy of prematurity stage 3 or higher, and
necrotizing enterocolitis and/or proven sepsis). The proportion
of adverse outcome (A) and of favourable outcome (B) with 95%-
confidence intervals and the number of infants per group are
shown. The dotted horizontal line indicates the average proportion
of the respective outcome. The dashed diagonal line represents the
regression line. ND, neurodevelopmental disability. The figure shows
data from 670 children because information on risk factor ROP
(stage 3 or higher) was not available in 14 of 684 patients.
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decreased. Neonatal mortality was predominantly de-
pendant on gestational age, birth weight z-score and
antenatal corticosteroids, while outcome at two years of
age in children surviving the neonatal period was best
predicted by BPD, ROP, and major brain lesions as diag-
nosed using head ultrasound examination. This study
provides representative national data, which may assist
in decisions on care of extremely preterm infants, and
which can contribute to improve both the quality of care
as well as the counselling of parents.
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